DE69840106D1 - Formulierungen für amylin peptidagonisten mit insulin - Google Patents

Formulierungen für amylin peptidagonisten mit insulin

Info

Publication number: DE69840106D1
Authority: DE; Germany
Prior art keywords: approximately; formulations; insulin; amylin; peptidagonists
Prior art date: 1998-01-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69840106T

Other languages

English (en)

Inventor

Italian James L

Shankar Musunuri

Cale Ruby

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amylin Pharmaceuticals LLC

Original Assignee

Amylin Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-09

Filing date

1998-01-09

Publication date

2008-11-20

1998-01-09 Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC

2008-11-20 Application granted granted Critical

2008-11-20 Publication of DE69840106D1 publication Critical patent/DE69840106D1/de

2018-01-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
102000004877 Insulin Human genes 0.000 title abstract 2
108090001061 Insulin Proteins 0.000 title abstract 2
108010041872 Islet Amyloid Polypeptide Proteins 0.000 title abstract 2
102000036770 Islet Amyloid Polypeptide Human genes 0.000 title abstract 2
229940125396 insulin Drugs 0.000 title abstract 2
238000009472 formulation Methods 0.000 abstract 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 abstract 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
229930195712 glutamate Natural products 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
108010029667 pramlintide Proteins 0.000 abstract 1
229960003611 pramlintide Drugs 0.000 abstract 1
NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 abstract 1
229940071643 prefilled syringe Drugs 0.000 abstract 1
239000003755 preservative agent Substances 0.000 abstract 1
230000002335 preservative effect Effects 0.000 abstract 1
150000005846 sugar alcohols Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Biophysics (AREA)
Dermatology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

DE69840106T 1998-01-09 1998-01-09 Formulierungen für amylin peptidagonisten mit insulin Expired - Lifetime DE69840106D1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1998/000288 WO1999034822A1 (en)	1998-01-09	1998-01-09	Formulations for amylin agonist peptides

Publications (1)

Publication Number	Publication Date
DE69840106D1 true DE69840106D1 (de)	2008-11-20

Family

ID=22266167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69840106T Expired - Lifetime DE69840106D1 (de)	1998-01-09	1998-01-09	Formulierungen für amylin peptidagonisten mit insulin

Country Status (9)

Country	Link
EP (1)	EP1044015B1 (de)
JP (1)	JP4353544B2 (de)
AT (1)	ATE410182T1 (de)
AU (1)	AU760609B2 (de)
CA (1)	CA2365742C (de)
DE (1)	DE69840106D1 (de)
DK (1)	DK1044015T3 (de)
ES (1)	ES2316161T3 (de)
WO (1)	WO1999034822A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2262647C (en)	1996-08-08	2007-12-04	Amylin Pharmaceuticals, Inc.	Methods for regulating gastrointestinal motility
US5783556A (en) *	1996-08-13	1998-07-21	Genentech, Inc.	Formulated insulin-containing composition
US7312196B2 (en) *	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
JP4647736B2 (ja) *	1999-09-30	2011-03-09	小林製薬株式会社	薬剤発散具
EP2036539A1 (de)	2007-09-11	2009-03-18	Novo Nordisk A/S	Stabile Formulierungen aus Amylin und dessen Analogen
CN101822822A (zh) *	2009-03-04	2010-09-08	北京德众万全药物技术开发有限公司	一种普兰林肽的药物组合物及其制备方法
JP2009149684A (ja) *	2009-03-11	2009-07-09	Amylin Pharmaceut Inc	アミリン作動薬ペプチド用製剤
CN102145164B (zh) *	2010-12-16	2013-02-27	深圳市健元医药科技有限公司	一种更加稳定的iapp类似物注射剂
US9399065B2 (en)	2012-04-16	2016-07-26	Biodel Inc.	Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PL2934568T3 (pl)	2012-12-21	2018-03-30	Sanofi	Agonista podwójny GLP1/GIP lub potrójny GLP1/GIP/glukagon
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080149A1 (de)	2013-12-13	2016-10-19	Sanofi	Duale glp-1-/glucagon-rezeptoragonisten
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
CA2947587C (en)	2014-05-02	2022-10-18	The Research Foundation For The State University Of New York	Islet amyloid polypeptides with improved solubility
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN107952064B (zh) *	2016-10-14	2023-10-20	江苏豪森药业集团有限公司	含有聚乙二醇洛塞那肽的药物制剂及其制备方法
US10463717B2 (en) *	2016-12-27	2019-11-05	Adocia	Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
WO2018144671A1 (en)	2017-02-01	2018-08-09	The Research Foundation For The State University Of New York	Mutant islet amyloid polypeptides with improved solubility and methods for using the same
EP4360651A3 (de)	2017-08-24	2024-07-17	Novo Nordisk A/S	Glp-1-zusammensetzungen und verwendungen davon
US11110063B2 (en)	2017-08-25	2021-09-07	MAIA Pharmaceuticals, Inc.	Storage stable sincalide formulations
TWI878456B (zh) *	2020-02-18	2025-04-01	丹麥商諾佛儂迪克股份有限公司	Glp-1組成物及其用途
EP4262747A1 (de) *	2020-12-16	2023-10-25	Zealand Pharma A/S	Pharmazeutische zusammensetzung von dualen glp-1-/glp-2-agonisten
IL312600A (en) *	2022-05-30	2024-07-01	Zealand Pharma As	Liquid formulations of amylin analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4654324A (en) *	1981-08-27	1987-03-31	Eli Lilly And Company	Human proinsulin pharmaceutical formulations
US5321008A (en) *	1991-01-10	1994-06-14	Amylin Pharmaceuticals, Inc.	Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
EP1162207A1 (de) *	1991-11-19	2001-12-12	Amylin Pharmaceuticals, Inc.	Amylinagonisten und ihre Verwendung
US6143718A (en) *	1995-06-07	2000-11-07	Amylin Pharmaceuticals, Inc.	Treatment of Type II diabetes mellutis with amylin agonists
US7910548B2 (en) *	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity

1998
- 1998-01-09 DE DE69840106T patent/DE69840106D1/de not_active Expired - Lifetime
- 1998-01-09 WO PCT/US1998/000288 patent/WO1999034822A1/en active IP Right Grant
- 1998-01-09 ES ES98902423T patent/ES2316161T3/es not_active Expired - Lifetime
- 1998-01-09 EP EP98902423A patent/EP1044015B1/de not_active Expired - Lifetime
- 1998-01-09 JP JP53493999A patent/JP4353544B2/ja not_active Expired - Fee Related
- 1998-01-09 AT AT98902423T patent/ATE410182T1/de not_active IP Right Cessation
- 1998-01-09 CA CA2365742A patent/CA2365742C/en not_active Expired - Fee Related
- 1998-01-09 DK DK98902423T patent/DK1044015T3/da active
- 1998-01-09 AU AU59094/98A patent/AU760609B2/en not_active Ceased

Also Published As

Publication number	Publication date
JP2002511103A (ja)	2002-04-09
ES2316161T3 (es)	2009-04-01
DK1044015T3 (da)	2008-12-08
AU5909498A (en)	1999-07-26
CA2365742C (en)	2013-04-30
EP1044015A4 (de)	2001-05-23
ATE410182T1 (de)	2008-10-15
CA2365742A1 (en)	1999-07-15
JP4353544B2 (ja)	2009-10-28
AU760609B2 (en)	2003-05-15
EP1044015B1 (de)	2008-10-08
EP1044015A1 (de)	2000-10-18
WO1999034822A1 (en)	1999-07-15

Publication	Publication Date	Title
DE69840106D1 (de)	2008-11-20	Formulierungen für amylin peptidagonisten mit insulin
US11872266B2 (en)	2024-01-16	Rapid-acting insulin compositions
CA2295140A1 (en)	1998-12-17	Stable insulin formulations
ES2569949T3 (es)	2016-05-13	Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
CA2090422C (en)	1996-02-13	Pharmaceutical composition of florfenicol
CN101141975B (zh)	2012-05-23	Vegf拮抗剂制剂
HU202761B (en)	1991-04-29	Process for producing stabilized erythropoietin compositions
Duane et al.	1971	Distribution, turnover, and mechanism of renal excretion of amylase in the baboon
US20060275353A1 (en)	2006-12-07	Stable topical drug delivery compositions
KR920003331B1 (ko)	1992-04-27	활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
ATE260651T1 (de)	2004-03-15	Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
WO2003101395A3 (en)	2004-10-14	Formulations for amylin agonist peptides
EA200700389A1 (ru)	2007-08-31	Стабильный при хранении инфузионный раствор дигидроптеридинонов
ES2089011T3 (es)	1996-10-01	Excipiente lipidico de administracion nasal y aplicacion topica.
SK282949B6 (sk)	2003-01-09	Stabilný vodný prostriedok, stabilný vodný roztok, výrobok, spôsob prípravy stabilného vodného prostriedku a sterilizovaná plniaca nádoba
JP2005538068A (ja)	2005-12-15	高濃度のヒト成長ホルモン（ｈＧＨ）とフェノールを含有する液剤
PT819010E (pt)	2004-01-30	Formulacao de proteina compreendendo factor viii ou factor ix de coagulacao numa solucao aquosa
ATE228005T1 (de)	2002-12-15	Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
KR19980031737A (ko)	1998-07-25	안정한 프로스타글란딘 e1-함유 주사제 조성물
CA1303992C (en)	1992-06-23	Stable injectable solutions of vinca dimer salts
JPH06247872A (ja)	1994-09-06	高濃度ｔｃｆ製剤
PT1305057E (pt)	2005-11-30	Composicao de biomateria microparticular para uso medicinal
US4963529A (en)	1990-10-16	Stable growth hormone releasing factor preparation
BR9803730A (pt)	2000-03-28	Preparados farmacêuticos de cilansetron estabilizados contra a racemização.
US4289783A (en)	1981-09-15	Etomidate-containing compositions

Legal Events

Date	Code	Title	Description
2009-10-29	8364	No opposition during term of opposition